EA202091116A1 - Наночастицы, содержащие синтетические варианты ганглиозида gm3, в качестве адъювантов в вакцинах - Google Patents
Наночастицы, содержащие синтетические варианты ганглиозида gm3, в качестве адъювантов в вакцинахInfo
- Publication number
- EA202091116A1 EA202091116A1 EA202091116A EA202091116A EA202091116A1 EA 202091116 A1 EA202091116 A1 EA 202091116A1 EA 202091116 A EA202091116 A EA 202091116A EA 202091116 A EA202091116 A EA 202091116A EA 202091116 A1 EA202091116 A1 EA 202091116A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- ganglioside
- adjuvants
- synthetic variants
- vaccines
- present
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 title abstract 3
- 239000002105 nanoparticle Substances 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 2
- PFJKOHUKELZMLE-VEUXDRLPSA-N ganglioside GM3 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 PFJKOHUKELZMLE-VEUXDRLPSA-N 0.000 title 1
- -1 GM3 ganglioside Chemical class 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 abstract 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 abstract 1
- 241000588650 Neisseria meningitidis Species 0.000 abstract 1
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 229940106189 ceramide Drugs 0.000 abstract 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 230000028996 humoral immune response Effects 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001144—Hormones, e.g. calcitonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
Abstract
Настоящее изобретение описывает способы получения наночастиц адъювантов, образованных различными синтетическими вариантами ганглиозида GM3. В зависимости от микроструктуры жирной кислоты в церамиде синтетического GM3 указанные адъюванты способны специфическим и специализированным образом стимулировать гуморальный или клеточный иммунный ответ против сопутствующих антигенов. В частности, согласно настоящему изобретению предложены иммуногенные вакцинные композиции, содержащие пептиды, полипептиды или белки и вышеупомянутые наночастицы, которые образуются посредством дисперсии гидрофобных белков комплекса наружной мембраны (ОМС) Neisseria meningitidis в растворах, содержащих полностью синтетические варианты ганглиозида GM3.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2017000137A CU24534B1 (es) | 2017-11-06 | 2017-11-06 | Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3 |
PCT/CU2018/050003 WO2019086056A1 (es) | 2017-11-06 | 2018-10-24 | Nano-partículas que contienen variantes sintéticas del gangliósido gm3 como adyuvantes en vacunas |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202091116A1 true EA202091116A1 (ru) | 2020-09-24 |
Family
ID=64745822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202091116A EA202091116A1 (ru) | 2017-11-06 | 2018-10-24 | Наночастицы, содержащие синтетические варианты ганглиозида gm3, в качестве адъювантов в вакцинах |
Country Status (18)
Country | Link |
---|---|
US (1) | US11806396B2 (ru) |
EP (1) | EP3711775A1 (ru) |
JP (1) | JP7332592B2 (ru) |
KR (1) | KR20200086315A (ru) |
CN (1) | CN111295200A (ru) |
AR (1) | AR114139A1 (ru) |
AU (1) | AU2018359358B2 (ru) |
BR (1) | BR112020008668A2 (ru) |
CA (1) | CA3079105A1 (ru) |
CO (1) | CO2020006548A2 (ru) |
CU (1) | CU24534B1 (ru) |
EA (1) | EA202091116A1 (ru) |
MX (1) | MX2020004644A (ru) |
NZ (1) | NZ764565A (ru) |
SG (1) | SG11202004180SA (ru) |
TW (1) | TWI719351B (ru) |
WO (1) | WO2019086056A1 (ru) |
ZA (1) | ZA202003218B (ru) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU24534B1 (es) | 2017-11-06 | 2021-07-02 | Ct Inmunologia Molecular | Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3 |
CU24637B1 (es) | 2019-12-24 | 2022-12-12 | Ct Ingenieria Genetica Biotecnologia | Polipéptidos que comprenden mutantes del vegf-a humano con re-arreglos de puentes disulfuro y composiciones que los contienen |
CU20200075A7 (es) | 2020-10-22 | 2022-05-11 | Ct Ingenieria Genetica Biotecnologia | Antígeno quimérico que comprende el dominio extracelular de pd-l1 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6149921A (en) * | 1993-12-29 | 2000-11-21 | Centro De Inmunologia Molecular | Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment |
IS4518A (is) * | 1997-07-09 | 1999-01-10 | Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group | Nýtt lyfjaform fyrir bóluefni |
PE20020572A1 (es) * | 2000-12-06 | 2002-07-31 | Centro Inmunologia Molecular | Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos |
CU23257A1 (es) * | 2003-02-27 | 2008-01-24 | Centro Inmunologia Molecular | COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA |
US7776346B2 (en) | 2003-05-22 | 2010-08-17 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Personal product compositions comprising structured benefit agent premix or delivery vehicle |
CU23739A1 (es) * | 2008-09-30 | 2011-12-28 | Ct Ingenieria Genetica Biotech | Composición farmacéutica utilizando combinaciones de variantes de la hormona liberadora de las gonadotropinas (gnrh) como inmunógeno |
US8343498B2 (en) * | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
CU24299B1 (es) * | 2013-08-02 | 2017-12-08 | Centro De Inmunología Molecular | Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico |
CU24534B1 (es) | 2017-11-06 | 2021-07-02 | Ct Inmunologia Molecular | Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3 |
-
2017
- 2017-11-06 CU CU2017000137A patent/CU24534B1/es unknown
-
2018
- 2018-10-24 BR BR112020008668-1A patent/BR112020008668A2/pt unknown
- 2018-10-24 CA CA3079105A patent/CA3079105A1/en active Pending
- 2018-10-24 CN CN201880071890.1A patent/CN111295200A/zh active Pending
- 2018-10-24 KR KR1020207016172A patent/KR20200086315A/ko not_active Application Discontinuation
- 2018-10-24 US US16/760,954 patent/US11806396B2/en active Active
- 2018-10-24 WO PCT/CU2018/050003 patent/WO2019086056A1/es unknown
- 2018-10-24 EP EP18822259.0A patent/EP3711775A1/en active Pending
- 2018-10-24 EA EA202091116A patent/EA202091116A1/ru unknown
- 2018-10-24 JP JP2020525926A patent/JP7332592B2/ja active Active
- 2018-10-24 AU AU2018359358A patent/AU2018359358B2/en active Active
- 2018-10-24 NZ NZ764565A patent/NZ764565A/en unknown
- 2018-10-24 SG SG11202004180SA patent/SG11202004180SA/en unknown
- 2018-10-24 MX MX2020004644A patent/MX2020004644A/es unknown
- 2018-10-25 TW TW107137740A patent/TWI719351B/zh active
- 2018-11-06 AR ARP180103229A patent/AR114139A1/es unknown
-
2020
- 2020-05-28 CO CONC2020/0006548A patent/CO2020006548A2/es unknown
- 2020-05-29 ZA ZA2020/03218A patent/ZA202003218B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2021501792A (ja) | 2021-01-21 |
CU24534B1 (es) | 2021-07-02 |
CO2020006548A2 (es) | 2020-08-21 |
US11806396B2 (en) | 2023-11-07 |
CN111295200A (zh) | 2020-06-16 |
BR112020008668A2 (pt) | 2020-10-06 |
WO2019086056A1 (es) | 2019-05-09 |
ZA202003218B (en) | 2022-05-25 |
CA3079105A1 (en) | 2019-05-09 |
SG11202004180SA (en) | 2020-06-29 |
JP7332592B2 (ja) | 2023-08-23 |
CU20170137A7 (es) | 2019-06-04 |
EP3711775A1 (en) | 2020-09-23 |
AU2018359358B2 (en) | 2022-08-04 |
AR114139A1 (es) | 2020-07-29 |
AU2018359358A1 (en) | 2020-06-11 |
MX2020004644A (es) | 2020-07-24 |
NZ764565A (en) | 2024-02-23 |
TW201927804A (zh) | 2019-07-16 |
US20200268878A1 (en) | 2020-08-27 |
TWI719351B (zh) | 2021-02-21 |
KR20200086315A (ko) | 2020-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019004913A (es) | Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm). | |
MX363529B (es) | Vesículas de membrana externa. | |
CY1124867T1 (el) | Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων | |
EA202091116A1 (ru) | Наночастицы, содержащие синтетические варианты ганглиозида gm3, в качестве адъювантов в вакцинах | |
WO2015130584A3 (en) | Lipid nanoparticle vaccine adjuvants and antigen delivery systems | |
EP4043031A3 (en) | Zika viral antigen constructs | |
EA201790239A1 (ru) | Молекула-носитель для антигенов | |
IE87439B1 (en) | Novel methods for manufacturing an adjuvant | |
EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
EA201790680A1 (ru) | Вакцины против вируса иммунодефицита человека (вич), содержащие один или более эписенсусных (episensus) для популяции антигенов | |
MX337202B (es) | Vacunas de conjugado carbohidrato-glicolipido. | |
MX2015010102A (es) | Vacuna de subunidades anti-mycoplasma spp. | |
WO2016191641A3 (en) | Methods for enhancing antigen-specific immune responses using combination therapy comprising papillomavirus capsid antigens | |
MX2019006104A (es) | Conjugados inmunogenicos y uso de los mismos. | |
MX2017008406A (es) | Conjugados de aminoacidos y peptidos y sus usos. | |
PH12014501795B1 (en) | Rotavirus subunit vaccines and methods of making and use thereof | |
EA202090319A1 (ru) | Пептидные конъюгаты, способ конъюгации и их использование | |
BR112017004181A2 (pt) | ?gene, vetor, célula hospedeira, partículas similares a vírus, vacina para vírus de papiloma humano, composição imunogênica, adjuvante, método para o preparo de uma vacina de papiloma humano, proteína de capsídeo principal e proteína hpv l1? | |
EA201990719A1 (ru) | Новые промоторы | |
EA201891639A1 (ru) | Аминокислотные и пептидные конъюгаты и способ конъюгации | |
EA201792512A1 (ru) | Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник | |
MX2019007924A (es) | Vacunas contra la influenza. | |
MX2019006105A (es) | Conjugados de vmen-antigeno y uso de los mismos. | |
BR112016021692A2 (pt) | Métodos de preparação de uma composição imunogênica e de aperfeiçoamento de potência imunoestimuladora de vacinas adsorvidas em sal de alumínio, composição imunogênica e uso de uma composição de l(mpla) | |
MX363149B (es) | Vacunas de nucleoproteina de la influenza. |